Gilead Sciences (NASDAQ:GILD) shares are ticking upwards after the healthcare major disclosed it has resolved litigation and patent challenges with major generic manufacturers including Lupin, Apotex, Macleods Pharma, Cipla, and Hetero Labs. The challenges were related to Gilead’s Descovy, Vemlidy, and Odefsey. Under the agreements, Gilead has granted a non-exclusive license in the U.S. to the generic manufacturers for patents related to tenofovir alafenamide (Descovy and Vemlidy) starting October 31, 2031, and for Odefsey starting January 31, 2032. The development implies that generic developers will be able to bring versions of these drugs on the market only after 2031 and 2032.
https://www.tipranks.com/news/gilead-sciences-nasdaqgild-ticks-higher-after-settling-patent-challenges?utm_source=advfn.com&utm_medium=referral